Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review
- 25 April 2022
- journal article
- review article
- Published by SAGE Publications in Vascular Medicine
- Vol. 27 (4) , 385-391
Abstract
Background: Despite strong association of elevated lipoprotein (a) (Lp(a)) levels with incident coronary and cerebrovascular disease, data for incident peripheral artery disease (PAD) are less robust. The main objective of the present systematic review was to analyze the association between elevated Lp(a) levels and PAD outcomes. Methods: This systematic review was performed according to PRISMA guidelines. A literature search was performed to detect randomized clinical trials or observational studies with a cohort design that evaluated the association between Lp(a) levels and PAD outcomes. Results: Fifteen studies including 493,650 subjects were identified and considered eligible for this systematic review. This systematic review showed that the vast majority of the studies reported a significant association between elevated Lp(a) levels and the risk of PAD outcomes. The elevated Lp(a) levels were associated with a higher risk of incident claudication (RR: 1.20), PAD progression (HR: 1.41), restenosis (HR: 6.10), death and hospitalization related to PAD (HR: 1.37), limb amputation (HR: 22.75), and lower limb revascularization (HR: 1.29 and 2.90). In addition, the presence of elevated Lp(a) values were associated with a higher risk of combined PAD outcomes, with HRs in a range between 1.14 and 2.80, despite adjusting for traditional risk factors. Heterogeneity of results can be explained by different patient populations studied and varying Lp(a) cut-off points of Lp(a) analyzed. Conclusion: This systematic review suggests that evidence is available to support an independent positive association between Lp(a) levels and the risk of future PAD outcomes. PROSPERO Registration No.: 289253.Keywords
This publication has 38 references indexed in Scilit:
- Lipoprotein (a) measurements for clinical applicationJournal of Lipid Research, 2016
- Effects of Extended-Release Niacin with Laropiprant in High-Risk PatientsNew England Journal of Medicine, 2014
- Assessing Bias in Studies of Prognostic FactorsAnnals of Internal Medicine, 2013
- Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Lipoprotein(a), Inflammation, and Peripheral Arterial Disease in a Community-Based Sample of Older Men and Women (the InCHIANTI Study)The American Journal of Cardiology, 2010
- Lipoprotein(a) and Other Serum Lipid Subfractions Influencing Primary Patency After Infrainguinal Percutaneous Transluminal AngioplastyJournal of Endovascular Therapy, 2009
- Symptomatic Peripheral Arterial Disease in WomenCirculation, 2008
- Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery StudyEuropean Heart Journal, 2007
- Risk Factors for Progression of Peripheral Arterial Disease in Large and Small VesselsCirculation, 2006
- Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: The Edinburgh Artery StudyAtherosclerosis, 2001